iRadimed (NASDAQ:IRMD) Sees Strong Trading Volume on Earnings Beat

iRadimed Corporation (NASDAQ:IRMD) shares saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings. 167,495 shares were traded during mid-day trading, an increase of 100% from the previous session’s volume of 83,589 shares.The stock last traded at $83.66 and had previously closed at $83.44.

The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS.

iRadimed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 45.71%.

Key Stories Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IRMD. Roth Mkm reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. Finally, Lake Street Capital reaffirmed a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $120.00.

Insider Buying and Selling

In other iRadimed news, CEO Roger E. Susi sold 3,750 shares of iRadimed stock in a transaction on Monday, April 27th. The shares were sold at an average price of $89.16, for a total transaction of $334,350.00. Following the completion of the sale, the chief executive officer owned 2,198,750 shares of the company’s stock, valued at approximately $196,040,550. The trade was a 0.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 48,750 shares of company stock worth $4,708,950. 36.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On iRadimed

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of iRadimed by 1.0% during the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock worth $40,313,000 after purchasing an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of iRadimed by 1.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock worth $21,123,000 after purchasing an additional 2,578 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after purchasing an additional 55,426 shares in the last quarter. Finally, State Street Corp boosted its position in shares of iRadimed by 3.1% during the fourth quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock worth $18,770,000 after purchasing an additional 5,713 shares in the last quarter. 92.34% of the stock is owned by institutional investors.

iRadimed Price Performance

The business’s 50-day moving average price is $96.69 and its two-hundred day moving average price is $94.02. The company has a market capitalization of $1.11 billion, a P/E ratio of 47.62 and a beta of 0.91.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.